Treatment of Type 1 Myotonic Dystrophy by Engineering Site-Specific RNA Endonucleases That Target (CUG)n Repeats

Molecular Therapy - United States
doi 10.1038/mt.2013.251
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Myotonic Dystrophy Type 1

CMAJ
Medicine
2016English

Rational Design of Bioactive, Modularly Assembled Aminoglycosides Targeting the RNA That Causes Myotonic Dystrophy Type 1

ACS Chemical Biology
BiochemistryMedicineMolecular Medicine
2012English

Disease Burden of Myotonic Dystrophy Type 1

Journal of Neurology
Neurology
2019English

Expanded CUG Repeats Dysregulate RNA Splicing by Altering the Stoichiometry of the Muscleblind 1 Complex

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2011English

Reversal of RNA Missplicing and Myotonia After Muscleblind Overexpression in a Mouse Poly(CUG) Model for Myotonic Dystrophy

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2006English

Dropped Head Presentation in Myotonic Dystrophy Type 1

Neurology India
Neurology
2005English

Design of a Bioactive Small Molecule That Targets the Myotonic Dystrophy Type 1 RNA via an RNA Motif–Ligand Database and Chemical Similarity Searching

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2012English

Nuclear Envelope Transmembrane Proteins in Myotonic Dystrophy Type 1

Frontiers in Physiology
Physiology
2018English

Recurrent Severe Rhabdomyolysis in a Pregnancy Affected by Myotonic Dystrophy Type 1

Pathology
Forensic MedicinePathology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy